Reviewing the Role of BTK Inhibitors for Hematologic Malignancies

Stay current on what advanced practitioners need to know about the BTK inhibitors, from MOA basics to key emerging data to selecting treatment and managing side effects.

Funding provided by an unrestricted educational grant from Pharmacyclics, an AbbVie Company, and Janssen Biotech, Inc.


Click the button below to download the Educator Module slide deck and presenter notes.


Download